CRIP1 functions as an oncogene in acute myeloid leukemia by modulating glycolytic metabolic reprogramming Authors: Muhammad Asif Zeb, Aamir Ali Khan, Ajaz Ahmad, Wentao Gui, Faryal Mehwish Awan, Bhavuk Dhamija, Sadiq Noor Khan Published: 2026 ABSTRACT AbstractAcute Myeloid leukemia (AML) is a stem cell-derived hematological malignancy associated with rapid progression and poor clinical outcome despite available treatments. CRIP1 exhibits tissue-specific activity, functioning as an oncogene in certain cancers while acting as a tumor suppressor in others. However, the role of CRIP1 and its association with metabolism in AML remains poorly investigated. To assess its metabolic role, a lactate release and a glucose consumption assay were performed, followed by gene expression analysis of LDHA, MCL1, and HK2 after CRIP1 knockdown. These results were confirmed through Western blot analysis. The CRIP1 knockdown and control cells were treated with 2-DG, a glycolytic inhibitor, and cell death was quantified using flow cytometry. The results showed a significant reduction in the proliferation of AML cells compared to the control, suggesting its oncogenic function. Elevated protein expression of Hexokinase 2, MCL1, and LDHA, suggests CRIP1’s involvement in regulating the glycolytic pathway. CRIP1 knockdown increased glycolytic dependence, and treatment with 2-deoxy-D-glucose (2-DG) selectively induced marked cell death in CRIP1-deficient cells, demonstrating that loss of CRIP1 renders AML cells highly susceptible to glycolytic inhibition. Treatment with 2-DG reduced glucose consumption and lactate production, consequently lowering cellular energy availability and inducing increased cell death. This study reveals a novel role for CRIP1 in AML progression through the modulation of glycolytic biomarkers, highlighting its potential as a therapeutic target.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-43411-0.Keywords: AML, CRIP1, Metabolism, Glycolytic biomarkers, 2-deoxy-D-glucose (2-DG)Subject terms: Biochemistry, Biotechnology, Cancer, Cell biology, Molecular biology, Biomarkers Introduction Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the clonal expansion of immature myeloid progenitor cells. These aberrant cells infiltrate the bone marrow microenvironment, impairing normal hematopoiesis, leading to reduced production of healthy blood cells1. Malignant transformation in AML arises from acquired genetic mutations, including gain-of-function alterations in proto-oncogenes and loss-of-function mutations in tumor suppressor genes, which collectively drive uncontrolled proliferation and impaired differentiation of the myeloid lineage2. Although AML accounts for only 15–20% of acute leukemia cases, it contributes disproportionately to leukemia-related mortality, representing approximately 30% of deaths, thereby underscoring its significant clinical burden3. Cysteine-rich protein 1 (CRIP1) is a member of the LIM/zinc-finger protein family, containing a zinc-binding domain that can assist in recruiting or positioning methyltransferase machinery, and is predominantly expressed in intestinal cells, where it contributes to zinc absorption and transport4. Besides its normal function, CRIP1 was found to have aberrant expression in various cancers, including gastric cancer5, colorectal cancer6, pancreatic cancer7, cervical cancer8, and thyroid cancer9, where it functions either as an oncogene or a tumor suppressor, suggesting its tissue-specific role. CRIP1 also plays an important role in regulating vital cancer signaling pathways, including Ras/AKT and Wnt/beta-catenin pathways, that drive cell proliferation, invasion, and metastasis in various cancers7. In multiple myeloma, a hematological malignancy, the aberrant expression of CRIP1 has been linked to enhanced proliferation, migration, and metastasis. Moreover, its upregulation has been correlated with poor prognosis and reduced overall survival10. Although advances in the treatment of hematological malignancies have improved patient outcomes, therapeutic outcomes remain suboptimal, necessitating the development of novel strategies. One promising approach involves targeting leukemia-specific metabolic vulnerabilities to disrupt cancer cell survival and progression11. Normal cells primarily depend on oxidative phosphorylation for energy generation, whereas cancer cells preferentially utilize aerobic glycolysis followed by lactate fermentation to produce ATP, even in oxygen-rich conditions, a metabolic reprogramming phenomenon known as the Warburg effect. In AML, through aerobic glycolysis, increased glucose consumption is not only necessary to yield ATP molecules by converting glucose to pyruvate and finally to lactate, but it is also important for feeding to the Krebs cycle for the synthesis of other essential metabolic intermediates, including amino acids, lipids, and nucleotides, indispensable for proliferation12. Therefore, to suppress the proliferation of AML, inhibiting glucose metabolism using glycolytic inhibitors is a promising strategy13. Results CRIP1 is preferentially upregulated in AML The candidate gene CRIP1 demonstrates tissue-specific differential expression patterns, as supported by TCGA database analyses. It is upregulated in certain malignancies, while it shows downregulation in others, suggesting a context-dependent, dual role in cancer biology (Fig. 1A and B). Given this complexity, elucidating whether CRIP1 functions as an oncogene or tumor suppressor in leukemia (AML) is crucial for unveiling its mechanistic contributions to AML pathogenesis, particularly in proliferation, metabolic reprogramming, and disease progression. Differential expression of CRIP1 in various cancers and in AML. (A, B) Bioinformatic analysis of CRIP1 mRNA expression across multiple cancer types (TCGA tumors) compared to matched normal tissues (GTEx), sourced from the GEPIA2 database. Expression values are log2(TPM + 1). Statistical significance was determined by one-way ANOVA with Tukey’s post-hoc test (*p* < 0.05). Cancer type abbreviations: KICH (kidney chromophobe a rare renal cell carcinoma), KIRC (Kidney Clear Cell Carcinoma), SKCM (Skin Cutaneous Melanoma), CHOL (Cholangiocarcinoma), PAAD (Pancreatic Adenocarcinoma), READ (Rectum Adenocarcinoma). (C) Relative mRNA expression of CRIP1 in the OCI-AML3 AML cell line compared to normal Bone Marrow Mononuclear Cells (BMMNCs) from healthy donors, measured by qPCR. Data are mean ± SD (n = 3). (D) Western blot analysis confirming elevated CRIP1 protein expression in OCI-AML3 cells versus BMMNCs. β-actin served as a loading control. This study analyzed and validated the upregulation of CRIP1 mRNA and its protein expression levels using quantitative PCR (qPCR) and western blotting. Results revealed that CRIP1 mRNA levels were significantly elevated in AML cell lines compared to non-neoplastic cell lines (Fig. 1C and D). These findings suggested that CRIP1 may have a potential oncogenic or tumor suppressor role in AML, warranting further exploration of its molecular mechanisms and functional implications. CRIP1 functions as an oncogene in AML To investigate the functional role of CRIP1 in AML, we performed targeted gene knockdown in the OCI-AML3 cell line using short hairpin RNA (shRNA) constructs. Knockdown efficiency was confirmed through both quantitative PCR (qPCR), which demonstrated an 88% reduction in CRIP1 mRNA levels (p < 0.01), and western blot analysis showing a significant reduction in protein levels (Fig. 2A and B). Scramble shRNA-transfected cells served as experimental controls. Following the confirmation of CRIP1 knockdown (CRIP1-KD), a proliferation assay was performed to evaluate the impact of CRIP1-KD on the growth characteristics of AML cells. The cells were incubated under optimal culture conditions (37 °C, 5% CO₂) for 24 h, and the mean number of live cells was recorded. The results revealed a significant reduction in the proliferation of OCI-AML3-CRIP1-KD cells, with a mean count of 1.9 × 10⁵ live cells, compared to 2.4 × 10⁵ live cells in the scramble control group (Fig. 2C). This reduction in proliferation was statistically significant (p = 0.02), indicating that silencing CRIP1 in the OCI-AML3 cell line markedly impairs the proliferative capacity of AML cells. Proliferation assay after CRIP1 knockdown. (A) mRNA expression of CRIP1 after knockdown. (B) Protein expression after CRIP1-KD. (C) CRIP1-KD effect inhibits the proliferation of AML. (D) The CRIP1-KD effect shows increased cell death as compared to SCR. In addition to cell proliferation, the proportion of dead cells was also analyzed to further explore the functional significance of CRIP1-KD in OCI-AML3. Trypan blue staining revealed a significant increase in the percentage of dead cells in the knockdown group compared to the scramble control. Notably, the mean percentage of dead cells in the scramble control group was 5.43%, and increased to 19.59% in OCI-AML3-CRIP1-KD cells (Fig. 2D). This difference was statistically significant (p = 0.0103), highlighting the crucial role of CRIP1 in maintaining cell viability in AML. The percentage of dead cells was confirmed using 7-AAD staining via flow cytometry (Fig. 6E). The results showed that the mean percentage of dead cells in CRIP1-KD cells was 23.65%, compared to 17.70% in the scramble control, which is statistically significant (p = 0.0018). Cell death analysis after treatment of SCR and CRIP1-KD cells with 2-DG. (A) Cell death in untreated SCR cells. (B) SCR cells treated with 2-DG (C) Cell death, untreated OCI-AML3-CRIP1-KD (D). Cell death of OCI-AML3–CRIP1-KD cells treated with 2-DG. (E) Percentage of cell death in SCR-UT, SCR-2DG, CRIP1-KD-UT, and CRIP1-KD-2-DG cells. Collectively, these findings underscore the oncogenic role of CRIP1 in AML. The gene appears to be essential for promoting cell proliferation and survival, whereas its silencing results in reduced proliferation and increased cell death. These observations provide important insights into the biological function of CRIP1 in AML and indicate that it may represent a potential therapeutic target for strategies aimed at limiting disease progression. Regulatory role of CRIP1 on glycolytic metabolic pathways CRIP1 has been implicated in the regulation of multiple cellular pathways, including metabolic processes, proliferative signaling such as the Wnt/β-catenin pathway, and other critical cancer-associated regulatory mechanisms across diverse malignancies. However, to the best of our knowledge, no studies to date have explored the role of CRIP1 in regulating metabolic pathways specifically in AML. Given the critical role of metabolic reprogramming in AML progression, we hypothesize that CRIP1 plays a pivotal role in controlling cellular metabolism, with a particular focus on glycolytic pathways. This study aims to investigate the potential relationship between CRIP1 and the regulation of glycolysis in AML, which could provide novel insights into its role in AML pathophysiology. To assess the metabolic role of CRIP1 in AML, we conducted a glucose consumption assay. The results revealed that OCI-AML3 cells with CRIP1 knockdown (CRIP1-KD) exhibited a markedly elevated glucose consumption rate (0.33320 µmol) relative to scramble (SCR) control cells (0.01981 µmol) (Fig. 3A). Statistical analysis confirmed that the knockdown of CRIP1 in the OCI-AML3 cell line significantly intensified glucose uptake and consumption compared to the SCR control group (p = 0.0417). Metabolic assay after CRIP1 knockdown. (A) Glucose consumption is increased in the CRIP1-KD cell than the SCR. (B) Lactate release assay revealed that CRIP1-KD cells released more lactate into the surrounding. To further support our findings, a lactate release assay was also performed to determine the downstream effects of enhanced glycolysis (Fig. 3B). The results revealed a marked difference in lactate release between SCR and CRIP1-KD cell lines. Specifically, the mean lactate release in SCR cells was 7.334 × 10⁻⁷ µmol, while the mean value in CRIP1-KD cells was 1.746 × 10⁻⁶ µmol. This increase in lactate release in CRIP1-KD cells was statistically significant (p = 0.0289), indicating an enhanced glycolytic flux in the absence of CRIP1. Collectively, these results suggest that CRIP1 plays a critical role in regulating glucose metabolism in AML, particularly by modulating glucose consumption and lactate production. The results confirmed that CRIP1-KD in the AML cell line led to increased lactate production, driven by enhanced glycolytic activity and elevated glucose consumption. CRIP1’s mechanistic role in regulating glycolytic marker expression Based on the key findings of increased glucose consumption and lactate release in OCI-AML3-CRIP1-KD cells, we systematically analyzed key glycolytic markers LDHA, HK2, and MCL1 in OCI-AML3-CRIP1-KD versus scramble control (SCR) cells using qPCR and western blot. Our findings validated CRIP1’s significant involvement in glycolytic regulation. Protein and gene expression analysis of glycolytic markers revealed a significant increase in both mRNA and protein levels of LDHA, HK2, and MCL1, with LDHA mRNA levels being significantly elevated in CRIP1-knockdown cells compared to SCR controls (p = 0.0239). Western blot analysis further confirmed this result, showing a four-fold increase in LDHA protein levels in OCI-AML3-CRIP1-KD cells, which was also statistically significant (p = 0.0250). In addition, the analysis of HK2, a critical glycolytic enzyme, demonstrated an upregulation in the mRNA level (p = 0.0198) in CRIP1-KD cells as compared to SCR control, while a 5.0-fold upregulation of HK2 protein (p = 0.0070) in CRIP1-KD cells. This substantial increase suggests enhanced glycolytic flux in the absence of CRIP1. Moreover, investigation of MCL1 expression also revealed upregulation in MCL1 mRNA levels (p = 0.0479) in OCI-AML3-CRIP1-KD cells compared to SCR controls. A more pronounced 4.5-fold elevation in MCL1 protein expression (p = 0.0002) was observed via western blot (Fig. 4). Gene expression and protein analysis of key glycolytic biomarkers following CRIP1 knockdown. (A) LDHA mRNA expression. (B) MCL1 mRNA expression. (C) HK2 mRNA expression. (D) Protein expression levels of LDHA, MCL1, and HK2 as determined by western blot. Representative blot images are shown. Data are presented as mean ± SD from three independent biological replicates. p < 0.05, *p < 0.01, p < 0.001 (Student’s t-test). To assess the effects of glycolytic inhibition on cell viability, we treated both scramble control (SCR) and CRIP1-knockdown (OCI-AML3-CRIP1-KD) cells with 10 mM 2-deoxyglucose (2-DG), a competitive glycolytic inhibitor. Cells were incubated for 24 h under standard culture conditions (37 °C, 5% CO₂), and the glucose consumption was quantified from the cell culture supernatant (Table 1). In control cells (SCR), 2-DG treatment resulted in reduced glucose consumption compared to untreated SCR cells (SCR-UT), though this difference did not reach statistical significance (p = 0.08). However, CRIP1-KD cells showed a more pronounced response, with 2-DG treatment causing a significant (p = 0.00) reduction in glucose consumption compared to untreated CRIP1-KD cells (Fig. 5A). Table 1Glucose uptake assay by the SCR control and CRIP1 knockdown cells treated with 2-DG.CellsMean Glucose uptake by the cells (µmol)P-ValueSCR-UT0.025630.08SCR-2-DG0.02070CRIP1-KD-UT0.030550.00CRIP1-KD-2DG0.02073SCR-UT0.025630.01CRIP1-KD-UT0.03055SCR-2-DG0.020700.98CRIP1-KD-2-DG0.02073 Glucose uptake assay by the SCR control and CRIP1 knockdown cells treated with 2-DG. Metabolic assays after treatment of SCR and CRIP1-KD cells with 2-DG. (A) Glucose consumption assay. (B) Lactate release assay. We further evaluated lactate production following 24-hour 2-DG treatment (Table 2). The results demonstrated that in scramble control (SCR) cells, 2-DG treatment reduced lactate production compared to untreated (SCR-UT) cells. However, this reduction did not reach statistical significance (p = 0.07). In CRIP1-KD cells, 2-DG treatment caused a significant (p = 0.01) decrease in lactate production versus untreated cells (Fig. 5B). Table 2Lactate released assay by the SCR control and CRIP1 knockdown cells treated with 2-DG.CellsMean Lactate release by the cells (µmol)P-ValueSCR-UT3.493e-0060.07SCR-2-DG3.102e-006CRIP1-KD-UT4.126e-0060.01CRIP1-KD-2DG3.602e-006SCR-UT3.493e-0060.01CRIP1-KD-UT4.126e-006SCR-2-DG3.102e-0060.02CRIP1-KD-2-DG3.602e-006 Lactate released assay by the SCR control and CRIP1 knockdown cells treated with 2-DG. These findings collectively indicate successful glycolytic inhibition by 2-DG, as evidenced by reduced glucose consumption and lactate production. Moreover, CRIP1-KD cells demonstrated enhanced sensitivity to glycolytic disruption. To evaluate the therapeutic potential of glycolytic inhibition, we quantified cell death using 7-AAD staining through flow cytometry after 24 h of 2-DG treatment (Fig. 6). The average percentage of dead cells in SCR-2DG-treated cells (22.80%) was higher than in SCR-untreated cells (17.75%), though this difference was not statistically significant, suggesting that SCR cells are less glycolytically dependent and exhibit resistance to 2-DG treatment (Table 3). In contrast, the CRIP1-knockdown cells treated with 2-DG showed a significantly higher average percentage of dead cells (35%) compared with the untreated CRIP1-knockdown cells (23.65%) (p = 0.00), indicating increased sensitivity to 2-DG due to their higher glycolytic activity. Additionally, when comparing treated SCR cells (22.80% cell death) to treated CRIP1-knockdown cells (35.75% cell death), the latter group showed significantly (p = 0.01) more cell death. Table 3Flow cytometry analysis of cell death of the SCR control and CRIP1 knockdown cells.CellsPercentage of cell death (%)P-ValueSCR-UT17.750.06SCR-2-DG22.80CRIP1-KD-UT23.650.00CRIP1-KD-2DG35.75SCR-UT17.750.00CRIP1-KD-UT23.65SCR-2-DG22.800.01CRIP1-KD-2-DG35.75 Flow cytometry analysis of cell death of the SCR control and CRIP1 knockdown cells. Overall, these findings demonstrate that the increased glycolysis-dependence of CRIP1-KD cells renders them more vulnerable to glycolytic inhibition by 2-DG, resulting in significantly elevated cell death. Consequently, 2-DG sensitizes CRIP1-KD cells to glycolytic disruption, indicating that targeting glycolysis may selectively compromise the viability of highly glycolysis-dependent cells, such as those with CRIP1 knockdown, while exerting minimal effects on cells with lower glycolytic activity. In AML cells with normal or high CRIP1 expression (left panel), CRIP1 functions as a transcriptional repressor, maintaining low expression of HK2, LDHA, and MCL1 and preserving balanced glucose utilization and lactate production. Following CRIP1 knockdown (right panel), loss of repression leads to strong induction of HK2, LDHA, and MCL1. MCL1 forms a functional complex with HK2 at the mitochondrial outer membrane, increasing HK2 activity and accelerating glycolytic throughput. Concurrently, elevated LDHA enhances pyruvate-to-lactate conversion, resulting in excessive lactate output and establishing a hyper-glycolytic metabolic state. This metabolic reprogramming creates a dependency on glycolysis, rendering CRIP1-KD AML cells acutely vulnerable to the glycolytic inhibitor 2-DG, which triggers energetic collapse and apoptotic cell death, Fig. 7. Mechanistic model of CRIP1-mediated glycolytic regulation in AML. Discussion CRIP1 exhibits differential expression across various cancers, and its role as a prognostic factor varies depending on the malignancy. In certain cancers, CRIP1 overexpression is associated with reduced overall survival, classifying it as a poor prognostic marker. Conversely, in other cancers, CRIP1 overexpression correlates with better treatment response, suggesting a favorable prognostic indicator14. Given these contrasting roles in cancer progression, it is essential to explore the function of CRIP1 in leukemia, particularly its involvement in cellular development, proliferation, and metabolic reprogramming. The present study focused on the mechanistic role of CRIP1 in the progression of AML through modulation of metabolic reprogramming, providing new insights into its function in this disease. Our results indicate that CRIP1 silencing significantly affects AML cell proliferation. CRIP1-KD cells exhibited markedly reduced proliferative capacity and increased cell death compared to controls. This observation supports the hypothesis that CRIP1 functions as an oncogene in the development of AML. Our mechanistic studies employed the OCI-AML3 cell line, a model characterized by an NPM1 mutation and a pronounced basal glycolytic rate. This choice was strategic to maximize the detection of CRIP1’s metabolic effects within a clinically relevant genetic context. We acknowledge that validation across a panel of AML cell lines representing diverse genetic backgrounds will be an important future step to generalize these findings. Supporting evidence from RNA sequencing studies in bone marrow samples from relapsed AML patients further corroborates this role, showing elevated CRIP1 levels in relapsed patients, which were statistically linked to decreased overall survival15. This aligns with findings in multiple myeloma10 and a variety of non-hematological malignancies, including gastric5, colorectal6, pancreatic7, cervical8, and thyroid cancers9, where CRIP1 has been consistently implicated as a promoter of tumor progression. The recurrent identification of CRIP1 as an oncogenic driver across diverse malignancies strengthens its potential as a clinically relevant biomarker and therapeutic target in AML. Metabolic reprogramming is a hallmark feature of cancer cells under stress, a phenomenon that is critical for tumorigenesis and resistance to treatment16. Cellular stress, resulting from disruptions in cellular homeostasis such as hypoxia, nutrient deprivation, and viral infections, leads cancer cells to adapt their metabolism to ensure survival and progression17. In this study, CRIP1-KD cells enhanced glucose consumption and lactate production, indicating a metabolic shift toward glycolysis as a stress-response survival mechanism. Lactate is an important byproduct produced during glycolysis that plays a key role in ATP generation within mitochondria, which is essential for tumor cells’ survival. Its reversible conversion is catalyzed by Lactate dehydrogenase (LDH)18. Since CRIP1-KD cells release more lactate, we assessed LDHA activity and observed a fourfold increase in LDHA protein levels. LDHA is frequently upregulated in cancers, and we observed in our study that it enhances glycolytic flux and promotes metabolic adaptation. To further validate our hypothesis, we analyzed additional glycolytic markers, including HK2 and MCL1. HK2 is one of the crucial enzymes involved in glycolysis, which catalyzes the phosphorylation of glucose, thereby trapping it within the cell and directing it toward energy production and the pentose phosphate pathway. Among the two isoforms of hexokinase, HK2 is the predominant one involved in cancer metabolism, particularly in the context of aerobic glycolysis19. In the present study, we observed a significant five-fold upregulation of HK2 protein expression in CRIP1-KD cells compared to the scramble controls. This upregulation likely contributes to the increased in glucose consumption and lactate production, which are necessary to sustain the energy demands of cancer cells’ survival under stress20. Additionally, MCL1, another important protein, was upregulated in CRIP1-KD cells, further promoting glycolytic activity. MCL1 binds to HK2 on the mitochondrial outer membrane, stimulating glycolysis and thereby supporting the energy requirements of cancer cells19. The concurrent upregulation of HK2 and MCL1 in CRIP1-KD cells highlights the metabolic reprogramming that enhances glycolytic activity and likely supports cell survival under stress. To further investigate the role of CRIP1, both SCR and CRIP1-KD cells were treated with 2-DG, a glycolytic inhibitor that targets hexokinase21. Following treatment with 2-DG, glucose consumption and lactate production were significantly reduced in CRIP1-KD cells compared to SCR cells, indicating that CRIP1 knockdown induced a more glycolytic phenotype. 2-DG inhibits hexokinase, thereby inhibiting the glycolytic pathway and depriving cells of the energy necessary for survival and proliferation22. As a result, CRIP1-KD cells exhibited a significantly higher percentage of cell death due to being more sensitive to 2-DG treatment compared to SCR cells. Interestingly, previous studies on OCI-AML3 cells have shown resistance to 2-DG treatment, with minimal changes in glucose consumption or lactate production23. However, in this study, the knockdown of CRIP1 induced a more glycolytic phenotype in these cells, rendering them more susceptible to glycolytic inhibition. This observation underscores the critical role of CRIP1 in regulating metabolic pathways and influencing the survival and proliferation of leukemia cells. To the best of our knowledge, this is the first study to investigate the role of CRIP1 in the metabolic reprogramming of AML cells. The results suggest that CRIP1 plays a critical role in regulating both cell proliferation and apoptosis, potentially through modulation of glycolytic activity. The enhanced glycolytic dependency observed in CRIP1-silenced cells highlights the potential therapeutic value of targeting CRIP1 or glycolysis-related pathways in AML. Given the promising effects of 2-DG treatment, CRIP1 may serve as an effective biomarker for prognostic and therapeutic applications. Our findings suggest that CRIP1 knockdown may compromise mitochondrial function, leading AML cells to increase glycolytic activity as a compensatory survival mechanism. Although direct measurements of mitochondrial respiration were not performed, the marked shift toward glycolysis in CRIP1-KD cells supports this hypothesis. Future investigations using Seahorse metabolic flux assays will enable simultaneous evaluation of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), alongside assessments of ATP production and mitochondrial membrane potential, to delineate how CRIP1 coordinates the balance between glycolysis and oxidative phosphorylation. The study is limited by the lack of in-vivo validation and reliance on a single CRIP1-targeting shRNA. Developing CRIP1-silenced xenograft models requires extensive ethical approvals, specialized metabolic imaging capabilities, and additional resources beyond the scope of the current work. While the shRNA used has been validated in AML systems, off-target effects cannot be entirely ruled out. Subsequent studies will employ multiple independent shRNAs and CRISPR-based gene editing to ensure specificity and further clarify CRIP1’s role in AML metabolic regulation. Overall, this work establishes a foundational mechanistic framework for understanding CRIP1-driven metabolic remodeling in AML and highlights key directions for future research, including mitochondrial function analyses, in vivo studies, and comprehensive genetic validation. Conclusion This study uncovers a previously uncharacterized oncogenic function of CRIP1 in acute myeloid leukemia (AML), demonstrating its pivotal role in promoting cellular proliferation and orchestrating metabolic reprogramming. CRIP1 modulates critical glycolytic regulators, including hexokinase-2 (HK2), LDHA, and MCL1, which collectively drive enhanced glycolytic flux. Silencing CRIP1 in OCI-AML3 cells induced a hyper-glycolytic phenotype, significantly increasing cellular susceptibility to glycolytic inhibition. Pharmacological blockade using 2-deoxy-D-glucose (2-DG) further potentiated apoptotic cell death, highlighting the metabolic dependency of CRIP1-expressing AML cells. These findings provide mechanistic insight into CRIP1-mediated metabolic vulnerabilities and support the potential of targeting glycolytic pathways as a therapeutic strategy in AML subtypes characterized by CRIP1-driven metabolic alterations, warranting further preclinical and clinical investigation. Methods Bioinformatic analysis The gene of interest, which is differentially expressed in various cancers, was analyzed in comparison with adjacent normal tissues using the TCGA database (http://gepia.cancer-pku.cn/ and http://tcga-data.nci.nih.gov/tcga/). We examined the prognostic value, clinical significance, and expression profiles of CRIP1 in the TCGA cohort. Cell culture The human acute myeloid leukemia cell line OCI-AML3 (ATCC CRL-2585) and the human embryonic kidney cell line HEK-293T (ATCC CRL-11268), were purchased from the American Type Culture Collection (ATCC). All the cells were maintained in RPMI 1640 medium (Gibco, MD, USA) supplemented with 10% FBS and (Gibco, MD, USA) and 1% penicillin and streptomycin. Cells were cultured at 37 °C in a humidified atmosphere at 5% CO2 according to the guidelines provided. Bone marrow mononuclear cells (BMMNCs) from healthy donors were used as normal controls for expression analyses. BMMNCs provide a physiologically relevant comparator population for AML studies and are commonly employed in leukemia transcriptional profiling. Generation of stable cell lines The lentivirus-based short hairpin RNA (shRNA) vectors targeting CRIP1-shRNA 5′ -AGCACGAAGGCAAACCCTACT-3' and scramble (SCR) lentiviral vectors were used as previously described24. Following 48 h. of incubation after transfection, puromycin (Cat. no. A1113803, Thermofisher Scientific) 2 µg/ml was added to the cultured cells for selection of knockdown cells for 7–14 days. Quantitative real-time PCR Total RNA was extracted using RNA extraction kit nucleospin (Ref. no. MN740955.250, MACHEREY-NAGEL, Germany) according to the manufacturer’s instructions. The iScrip cDNA synthesis kit (Cat. no. 1708890, Bio-Rad, USA) was used for the synthesis of cDNA according to the manufacturer’s instructions. For gene expression evaluation, qPCR was performed using Eva green kit (Cat. no. 186–4033, Bio-Rad, USA). The thermocycler condition was set with the previously reported methodology25. The following primers were used in this study, CRIP1; F-5’ CCTGCCTGAAGTGCGAGAAAT 3’, R-5’ CCTTTAGGCCCAAACATGGC 3’, LDHA; F 5’ TTGACCTACGTGGCTTGGAAG 3’, R- 5’ GGTAACGGAATCGGGCTGAAT 3’, MCL1; F- 5’ GGACATCAAAAACGAAGACG 3’, R-5’ GCAGCTTTCTTGGTTTATGG 3’, HK2; F- 5’ TGCAGCGCATCAAGGAGAACAAAG 3’, R- 5’ ACGGTCTTATGTAGACGCTTGGCA 3’, GUSB; F- 5’ CTACTTGAAGATGGTGATCGCTC 3’, R- 5’ ACAGATCACATCCACATACGG 3’. For normalization, GUSB was used as an internal control. Cell proliferation and dead cells assay The cell proliferative potential was evaluated using trypan blue staining. The cells were seeded in a 12-well plate at 1 × 105 cells/well. The plates were incubated in a humidified incubator at 37˚C with 5% CO2 for 24 h. After the 24-hour incubation period, the cells were mixed with trypan blue stain at a 1:5 dilution ratio. Live and dead cells were counted in four large squares of a Neubauer chamber. The percentage of dead cells was also confirmed through flow cytometry analysis using 7-AAD staining. Lactate release assay The cell lines previously cultured were harvested and centrifuged using 3000 RPM for 5 min, and the supernatant was collected. Lactate release assay was performed using L-Lactate Dehydrogenase (cat. no. 10127230001, Merk) and β-Nicotinamide adenine dinucleotide hydrate (cat. no. N7004-250MG, Merk) from the supernatant collected after centrifuging the cells. 10ul of the supernatant was added in duplicate to the respective wells from the samples. To each well, 290 µL 0.2 Molar glycine/hydrazine buffer (pH 9.2) was added and incubated at 37 °C for 30 min. The samples were analyzed through a microplate reader using 340 nm, and the results were recorded. Glucose consumption assay The glucose uptake assay was performed from the supernatant using the glucose oxidase/peroxidase (GOPOD) method. The supernatant was collected from SCR and OCI-AML3-CRIP1-KD cells through centrifugation. In 96-well plates, 10ul of supernatant was added in duplicate in corresponding wells along with 40ul of phosphate buffer. One ml reagent mixture was prepared by mixing 20ul Glucose oxidase (cat. no. G7141, sigma), 10ul o-Dianisidine dihydrochloride (D3252, sigma), 2ul horseradish peroxidase (P8375) and 968ul Phosphate buffer (17202, sigma). From the mixture, 50ul reagents were added to each well and the plate was incubated at 37 °C for 30 min. After 30 min, 50 µl of 37% HCL was added to stop the reaction. The samples were analyzed through a microplate reader using 540 nm, and the results were recorded. Although Seahorse ECAR and OCR assays offer comprehensive measurements of metabolic flux, these experiments were not feasible due to limited instrument availability during the study period. Instead, validated biochemical assays measuring glucose consumption and lactate production were employed as widely accepted surrogate indicators of glycolytic activity. ECAR and OCR profiling will be incorporated in future studies to provide complementary insights into cellular metabolism. Flow cytometry analysis To evaluate cell death, 1 × 10⁵ CRIP1-KD and SCR cells were treated with 2-DG and incubated at 37 °C in a humidified atmosphere containing 5% CO₂. After 24 h, the cells were washed with PBS and stained with 7-AAD (cat. no. 555815, BD Via-Probe™) following the manufacturer’s instructions. Flow cytometry analysis was performed using a BD FACS Canto II instrument. Western blotting analysis Total protein was extracted using cell lysis buffer (Beyotime Institute of Biotechnology) supplemented with a protease and phosphatase inhibitor cocktail (Beyotime Institute of Biotechnology). The protein concentration was quantified using a bicinchoninic acid protein assay kit (Ref. no. 23227, Thermofisher Scientific) according to the manufacturer’s protocol. Western blot analysis was performed as previously described25. The membranes were then subjected to immunoblotting with the appropriate primary antibodies, including LDHA; (cat. no. 3582; 1:1,000; Cell Signaling Technology) and MCL1 (cat. no. 4572; 1:1,000; Cell Signaling Technology.), HK2; (cat.no. 2867; 1:1000; cell signaling technology) at 4˚C overnight and Goat anti-rabbit (HRP) secondary antibodies (cat. no. 14708; 1:5,000; cell signaling technology) for 2 h at room temperature. The Beta-actin antibody (cat. no. 4967; 1:3,000; Cell Signaling) was used as a control. Signals were visualized using the BeyoECL Moon super sensitivity detection kit (Beyotime Institute of Biotechnology) according to the manufacturer’s protocol, and the blots were quantified using Image Pro Plus v6.0 software (Media Cybernetics, Inc.). Statistical analysis The Data were presented as the mean ± standard deviation using GraphPad Prism version 6.0 (GraphPad Software, Inc.). The student t-test was used to determine the significance level between two groups, and the data was represented in graphical form. All experiments were performed using a minimum of three biological replicates unless otherwise indicated. Quantitative PCR (qPCR) assays were conducted with three biological replicates, each analyzed in technical duplicates. Western blot analyses were repeated in three independent experiments. Glucose consumption and lactate production assays were performed in triplicate. Flow cytometric analysis of 7-AAD–stained cells was conducted using three independent biological replicates. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Acknowledgements The publication charges for this article are partially/fully borne from Khyber Medical University Publication Fund (No. DIR/ORIC/Ref/25/00106). The authors are also grateful to the Ongoing Research Funding Program, (ORF-2026-350), King Saud University, Riyadh, Saudi Arabia. Author contributions Muhammad Asif Zeb, Dr. Sadiq Noor Khan, Dr. Faryal Mehvish Awan, Dr. Ajaz Ahmad, and Dr. Aamir Ali Khan conceived the idea. Muhammad Asif Zeb, Dr. Bhavuk Dhamija, and Wentao Gui performed and validated the experiments. Bioinformatics and statistical analysis were performed by Dr. Faryal Mehwish Awan. Dr. Aamir Ali Khan and Dr. Sadiq Noor Khan provide overall supervision. Funding No Funding. Data availability The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Change history 6/18/2026 The original online version of this Article was revised: In the original version of this Article, the Acknowledgements was incorrect. The Acknowledgements section now reads: “The publication charges for this article are partially/fully borne from Khyber Medical University Publication Fund (No. DIR/ORIC/Ref/25/00106). The authors are also grateful to the Ongoing Research Funding Program, (ORF-2026-350), King Saud University, Riyadh, Saudi Arabia.” The original Article has been corrected. Contributor Information Aamir Ali Khan, Email: aamir.lakki@kmu.edu.pk. Sadiq Noor Khan, Email: snkhan@uoh.edu.pk. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Data Availability Statement The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.